Loading...
Market
What will be the outcome of Sangamo's BLA for ST-920 by end of 2026?
2
Resolution / Starting Odds
Approved • 25%
Rejected • 25%
Request for more data • 25%
Other • 25%
FDA official announcements or Sangamo Therapeutics' press releases
Story
Sangamo Therapeutics Aligns with FDA for Accelerated Approval of ST-920 Gene Therapy for Fabry Disease by 2025
Oct 22, 2024, 12:12 PM
Sangamo Therapeutics announced that it has reached an agreement with the U.S. FDA on an Accelerated Approval pathway for its ST-920 gene therapy product candidate for the treatment of Fabry disease. This alignment is expected to accelerate the potential approval timeline by approximately three years, with a Biologics License Application (BLA) submission anticipated in the second half of 2025. The FDA's decision is a significant step forward for Sangamo's efforts in addressing this rare disease.
View original story
Similar markets
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Up by more than 50% • 25%
Up by 0% to 50% • 25%
Down by 0% to 50% • 25%
Down by more than 50% • 25%
Yes • 50%
No • 50%
Significant efficacy • 25%
Moderate efficacy • 25%
No efficacy • 25%
Inconclusive results • 25%
Less than 10% • 25%
10% to 25% • 25%
25% to 50% • 25%
More than 50% • 25%
Less than 1,000 • 25%
1,000 to 5,000 • 25%
5,000 to 10,000 • 25%
More than 10,000 • 25%
Highly positive • 25%
Moderately positive • 25%
Neutral • 25%
Negative • 25%
Less than $100 million • 25%
$100 million to $500 million • 25%
$500 million to $1 billion • 25%
More than $1 billion • 25%
Accelerated Approval • 25%
Full Approval • 25%
Conditional Approval • 25%
No Approval • 25%
Successful • 25%
Partially Successful • 25%
Unsuccessful • 25%
No Data Released • 25%